European pharma peers to close valuation gap with AstraZeneca by 2028
Resolves: The average valuation premium (measured as P/E ratio or enterprise value to sales) of Novartis and Roche relative to AstraZeneca on 2028-07-11 is at least 20% lower than their average premium on 2026-07-11.
European pharma peers to close valuation gap with AstraZeneca by 2028
Market overview
AstraZeneca's pipeline premium has been a key differentiator among European pharma firms. If investor confidence wanes due to recent trial failures, competitors like Novartis and Roche may see their valuations converge with AstraZeneca's, reducing the premium gap by 2028 as perceived risk normalizes.
macro prediction market
- Implied probability (Yes)
- 60%
- Closes
- 2028-07-11
About this prediction
Resolution criteria
The average valuation premium (measured as P/E ratio or enterprise value to sales) of Novartis and Roche relative to AstraZeneca on 2028-07-11 is at least 20% lower than their average premium on 2026-07-11.
Source: user-generated
More macro markets
- 10-year Treasury yield exceeds 5% by Q4 2026 due to Fed oversight — 67% Yes
- Ukraine aid funding drops 20% in next federal budget cycle — 70% Yes
- US new business filings surpass 2026 record by 2027 — 75% Yes
- Fed holds interest rates steady through 2026 due to labor stability — 70% Yes
- Fed cuts rates within 6 months under Warsh — 70% Yes
- AI boosts oil production by 5%+ by 2027 — 70% Yes
- U.S. energy production hits new annual record in 2026 — 80% Yes
- Trump's approval rating drops below 40% by year-end — 70% Yes